Login to Your Account



Pre-IPO Hutchison kicks off China phase III trial for NETs drug sulfatinib

By Shannon Ellis
Staff Writer

Tuesday, December 22, 2015

SHANGHAI – Hutchison Medipharma Ltd., of Shanghai, one of China's biotech pioneers with a deep pipeline of small-molecule oncology and autoimmune candidates, has started dosing Chinese patients with neuroendocrine tumors (NETs) in a phase III trial of sulfatinib.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription